• Publications:
• Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer
• Synopsis: IFCT-2203_synopsis_v2.0_20240119_IFCT.pdf